Atrasentan銷售預測與市場規模分析（2034 年）

Atrasentan成長的關鍵促進因素

1. 擴大市場佔有率並增加新患者數量

• Atrasentan是一種選擇性內皮素 A (ETA) 受體拮抗劑，已成為 IgA腎臟病(IgAN) 的一種有前景的疾病修正治療，而 IgA 腎病是一種核准治療選擇有限的疾病。
• 腎臟科醫師的認知不斷提高，以及強力的後期臨床試驗數據有望促進更早地採用和新患者開始治療，尤其是在持續蛋白尿的高風險 IgAN 患者中。
• 隨著治療模式從支持性治療和類固醇轉向以機制為基礎的標靶治療，預計商業性發展勢頭也將增強。

2. 主要適應症的擴展

• IgA腎臟病（主要目標）：專為IgA腎病變進展高風險患者研發。顯著降低蛋白尿和腎臟保護徵兆。
• 慢性腎臟病(CKD) 亞型：鑑於內皮素訊號在腎臟疾病進展中的核心作用，可以對其在更廣泛的蛋白尿 CKD 患者群體中的潛在用途進行長期探索。
• 聯合治療的潛力：Atrasentan有潛力與 RAAS 抑制劑和 SGLT2 抑制劑等標準療法聯合使用，從而加強其在綜合腎臟疾病管理中的作用。
• 產品線拓展機會：IgAN 的成功可能會推動產品生命週期拓展到其他罕見和進行性腎絲球疾病。

3. 地理擴張

• 美國和歐洲作為核心市場：初步的商業化活動預計將集中在擁有成熟的腎臟病網路和強大的罕見疾病報銷框架的地區。
• 亞太地區的成長潛力：中國和日本等國家 IgAN 的高發病率使亞太地區成為一個重要的長期成長地區，但需獲得監管部門的核准。
• 全球發展策略：提高人們對 IgAN 是進行性且可治療的疾病（而不是良性疾病）的認知，將有助於更廣泛地在區域內推廣應用。

4. 新適應症的核准

• IgAN 的監管申報：在 3 期臨床試驗取得積極結果後，計劃向 IgAN 提交監管申報，這標誌著在滿足高度未滿足需求的核准方面邁出了重要一步。
• 核准的可能性：利用替代終點（例如蛋白尿減少）可能有助於加速核准，但需後續確認數據。
• 加強產品組合：Atrasentan的核准顯著加強了贊助商的腎臟產品組合，並將收入多元化至罕見腎臟疾病領域。

5. IgA腎病變患者數量呈現顯著成長趨勢

• 未滿足的醫療需求很高：儘管採取了最佳的支持性治療，但許多 IgAN 患者仍會發展為末期腎病。
• 令人信服的療效徵兆：持續且具有臨床意義的蛋白尿減少有望推動腎臟科醫師大力開立處方。
• 治療模式的改變：隨著人們對 IgAN早期療育的接受度不斷提高，預計長期來看，患者數量將持續成長。

6. 競爭差異化與市場趨勢

• 標靶 ETA 受體阻斷：Atrasentan具有特異性的作用機制，可減少蛋白尿，同時避免選擇性較低的藥物所引起的廣泛的內皮素相關副作用。
• 口服療法的便利性：與注射劑或更複雜的治療方法相比，每日一次口服給藥有助於提高患者的依從性。
• 與精準腎臟病學趨勢相符：鑑於人們越來越關注基於生物標記的風險分層和早期疾病干預，Atrasentan處於有利地位。
• 真實世界數據 (RWE) 的重要性日益凸顯：核准後，真實世界數據對於確保支付方的信心、檢驗長期安全性以及推進治療指南至關重要。

Atrasentan的最新趨勢

2025年4月，諾華公司宣布，美國食品藥物管理局（FDA）加速批准了腎臟病（Atrasentan）上市，這是一種原發性且選擇性的內皮素A（ETA）受體拮抗劑，用於降低原發性IgA腎病（IgAN）成人患者的蛋白尿，蛋白尿通常定義為快速/肌酸酐 5.55965/202550005/225925055 -g + /核准的風險。 VANRAFIA為每日一次的非類固醇口服藥物，可與包括腎素-血管收縮素系統（RAS）抑制劑（可合併或不合併SGLT2抑制劑）在內的支持性治療合併使用。

《Atrasentan銷售預測及市場規模分析（2034）》報告已通過核准分析了阿曲生坦在七大主要市場（美國、歐盟四國（德國、法國、義大利和西班牙）、英國、法國、義大利和西班牙）的已核准適應症，以及潛在適應症，例如修格蘭氏症候群全身性紅斑性狼瘡、新生兒同種免疫性血小板減少症、乾燥症和系統性紅斑狼瘡。本報告詳細分析了Atrasentan在七大主要市場（美國、歐盟四國（德國、法國、義大利和西班牙）、英國和日本）的現有用途、已通過核准，Atrasentan週期為2020年至2034年。此外，報告也對Atrasentan已通過核准和潛在適應症進行了詳細描述。這份Atrasentan市場報告深入分析了Atrasentan的銷售預測、作用機制、劑量和給藥途徑，以及研發和其他開發活動，包括監管里程碑。此外，該報告還對市場進行了詳細分析，包括Atrasentan過去和當前的市場表現、未來市場評估（包括對七個主要國家已通過核准和潛在適應症的Atrasentan市場預測分析）、SWOT分析、分析師觀點、市場競爭對手的全面概述，以及針對每種適應症的其他新興治療方法的概述。報告中還對Atrasentan的銷售預測和市場促進因素進行了分析。

Atrasentan藥物概述

Atrasentan（VANRAFIA）是由諾華公司研發的一種口服選擇性內皮素A受體（ETAR或ETA）拮抗劑，用於治療免疫球蛋白A腎臟病（IgAN），這是進行性腎臟疾病。它具有高度選擇性（ETA的Ki值為0.034 nM，ETB的Ki值為63.3 nM），可抑制內皮素-1與腎臟細胞上ETA受體的結合。這可以減輕腎絲球高血壓、遠端小動脈血管收縮、發炎、纖維化和蛋白尿，同時保護腎功能。該藥於2025年獲得美國食品藥物管理局（FDA）核准，用於治療有快速進展風險的IgAN成人患者。每日一次（0.75 mg）給藥，需合併標準症狀治療，包括腎素-血管收縮素系統阻斷劑。第三期臨床研究證實，阿曲生坦可顯著降低蛋白尿。本報告提供有關Atrasentan在多種適應症中的銷售情況、成長抑制因素和促進因素、使用情況和核准情況的資訊。

Atrasentan目前處於 II 期臨床開發階段，用於治療 IgA腎臟病患者（NCT04573920）。

Atrasentan市場報告的研究範圍

本報告深入分析了以下內容：

• 對Atrasentan進行全面的產品概述，包括其作用機制（MoA）、產品說明、劑量和給藥方法，以及針對核准適應症（如重症肌無力）和潛在適應症（如胎兒紅血球增多症、新生兒同種免疫性血小板減少性疾病、修格蘭氏症候群和全身性紅斑性狼瘡）的研究和開發活動。
• 這份Atrasentan市場報告提供了有關監管里程碑和其他發展活動的詳細資訊。
• 該報告還重點介紹了Atrasentan在美國、歐洲和日本已通過核准和潛在適應症的成本估算和區域差異、已報告和估計的銷售額以及研發活動。
• 這份Atrasentan市場報告還涵蓋了專利資訊、學名藥上市及其對降低成本的影響。
• 這份Atrasentan市場報告包含了Atrasentan在已通過核准和潛在適應症範圍內的當前和預測銷售情況，直至 2034 年。
• 此外，也全面介紹了每種適應症中新興的後期治療方法。
• 這份Atrasentan市場報告還包括對Atrasentan在已通過核准和潛在適應症方面的 SWOT 分析和分析師觀點。

調查方法：

本Atrasentan市場報告主要基於從內部資料庫、一手和二手研究以及DelveInsight行業專家團隊的內部分析中獲得的數據和資訊。二級資訊來源和非印刷管道，例如搜尋引擎、新聞網站、世界各地的監管機構網站、行業期刊、白皮書、雜誌、書籍、行業協會、貿易入口網站以及對現有資料庫的存取。

DelveInsight的Atrasentan分析觀點

• 對Atrasentan市場的詳細評估

這份Atrasentan銷售市場預測報告對七個主要市場——美國、歐盟四國（德國、法國、義大利、西班牙）、英國和日本——進行了核准的市場評估，涵蓋了已獲批准的適應症（如重症血小板減少性疾病、新生兒同種免疫性血小板減少症、修格蘭氏症候群和全身性紅斑性狼瘡）。報告的這一部分提供了阿曲生Atrasentan截至2034年的當前銷售數據和預測銷售數據。

• Atrasentan的臨床評價

這份Atrasentan市場報告提供了有關Atrasentan已通過核准和潛在適應症的臨床試驗資訊，包括研究干預措施、研究條件、實驗狀況以及開始和完成日期。

Atrasentan的競爭格局

本報告深入分析了該領域的競爭對手和市售產品，並概述了新興產品及其預計上市日期，這些產品將成為市場上的主要競爭者。

Atrasentan市場潛力及收入預測

• Atrasentan及其主要適應症：預計市場規模
• Atrasentan的預期銷售潛力（銷售尖峰時段預測）
• Atrasentan定價策略和報銷情況

Atrasentan競爭訊息

• 在研競爭藥物數量（研發管線分析）
• Atrasentan與現有療法相比的市場定位
• Atrasentan坦相對於競爭對手的優勢和劣勢

Atrasentan監理與商業里程碑

• Atrasentan的關鍵監管核准和預計上市時間
• 商業合作、授權協議和併購活動

Atrasentan的臨床鑑別診斷

• 與現有藥物相比，Atrasentan具有更優的療效和安全性
• Atrasentan的獨特優勢

Atrasentan市場報告要點

• 未來幾年，隨著阿曲生坦的廣泛應用、處方箋的增加以及在多種免疫學適應症中的更廣泛應用，預計Atrasentan市場將發生變化，這將推動市場規模的成長。
• Atrasentan相關企業正在開發以治療和改善疾病狀態的新方法為重點的治療方法，以評估可能影響Atrasentan優勢的挑戰和機會。
• 其他用於治療重症肌無力的新興產品，以及胎兒紅血球增多症、新生兒同種免疫性血小板減少性疾病、修格蘭氏症候群和全身性紅斑性狼瘡等潛在適應症，預計將對Atrasentan構成激烈的市場競爭，而近期推出的後期治療方法預計也將對市場產生重大影響。
• 它提供了Atrasentan在已通過核准和潛在適應症中的最新進展情況，並詳細說明了監管里程碑和研發活動。
• 分析Atrasentan的成本、定價趨勢和市場定位，以支持免疫學領域的策略決策。
• 我們對Atrasentan銷售預測數據（截至 2034 年）的詳細分析將幫助您決策流程，透過確定Atrasentan在已通過核准和潛在適應症中的整體情況。

目錄

第1章 報告概述

第2章Atrasentan概述：核准的適應症，例如重症肌無力；以及潛在的適應症，例如胎兒紅血球增多症、新生兒同種免疫性血小板減少性疾病、修格蘭氏症候群和全身性紅斑性狼瘡。

• 產品詳情
• Atrasentan的臨床開發
  • Atrasentan的臨床研究
  • Atrasentan臨床試驗資訊
  • 安全性和有效性
• 其他發展活動
• 產品簡介

第3章Atrasentan（上市治療藥物）的競爭格局

第4章 競爭格局（後期Atrasentan療法）

第5章Atrasentan市場評估

• Atrasentan在已通過核准和潛在適應症的市場展望
• 對七個主要國家的分析
  • Atrasentan在七個主要國家已已通過核准和潛在適應症的市場規模
• 各國市場
  • Atrasentan（已通過核准和潛在適應症）在美國的市場規模
  • Atrasentan在德國的市場規模（已通過核准和潛在適應症）
  • 英國Atrasentan市場規模（已通過核准和潛在適應症）

第6章Atrasentan的SWOT分析

第7章 分析師觀點

第8章附錄

第9章 DelveInsight 服務

第10章 免責聲明

第11章 關於 DelveInsight

第12章 報告購買選項

Key Factors Driving Atrasentan Growth

1. Market Share Gains and New Patient Starts

• Atrasentan, a selective endothelin A (ETA) receptor antagonist, is emerging as a high-potential disease-modifying therapy in IgA nephropathy (IgAN), a condition with limited approved treatment options.
• Growing nephrologist awareness and strong late-stage clinical data are expected to drive early adoption and new patient starts, particularly among high-risk IgAN patients with persistent proteinuria.
• Commercial momentum is anticipated as treatment paradigms shift from supportive care and steroids toward targeted, mechanism-based therapies.

2. Expansion Across Key Indications

• IgA Nephropathy (Primary Focus): Atrasentan is being developed for patients with IgAN at high risk of progression, supported by robust reductions in proteinuria and favorable kidney protection signals.
• Chronic Kidney Disease (CKD) Subsets: Given the central role of endothelin signaling in kidney disease progression, there is longer-term potential to explore use in broader proteinuric CKD populations.
• Combination Therapy Potential: Atrasentan may be positioned alongside standard-of-care therapies such as RAAS inhibitors and SGLT2 inhibitors, strengthening its role in comprehensive renal disease management.
• Pipeline Expansion Opportunities: Success in IgAN could enable lifecycle expansion into other rare or progressive glomerular diseases.

3. Geographic Expansion

• U.S. and Europe as Core Markets: Initial commercialization efforts are expected to focus on regions with established nephrology networks and strong rare-disease reimbursement frameworks.
• Asia-Pacific Growth Potential: High IgAN prevalence in countries such as China and Japan positions Asia-Pacific as a significant long-term growth region, pending regulatory approvals.
• Global Development Strategy: Broader geographic expansion will be supported by increasing recognition of IgAN as a progressive, treatable disease rather than a benign condition.

4. New Indication Approvals

• Regulatory Filings in IgAN: Positive Phase III outcomes support planned regulatory submissions for IgAN, representing a major step toward approval in a high-unmet-need indication.
• Potential for Accelerated or Conditional Pathways: Use of surrogate endpoints such as proteinuria reduction may facilitate earlier approvals, with confirmatory outcomes data to follow.
• Portfolio Strengthening: Approval of atrasentan would significantly enhance its sponsor's renal portfolio and diversify revenue into rare kidney diseases.

5. Strong IgAN Volume Momentum

• High Unmet Clinical Need: Many IgAN patients continue to progress to end-stage kidney disease despite optimized supportive care.
• Compelling Efficacy Signals: Consistent and clinically meaningful reductions in proteinuria are expected to drive strong prescribing momentum among nephrologists.
• Shifting Treatment Paradigms: Increasing acceptance of early intervention in IgAN is expected to support sustained patient volumes over time.

6. Competitive Differentiation and Market Trends

• Targeted ETA Receptor Blockade: Atrasentan offers a focused mechanism that reduces proteinuria while avoiding broader endothelin-related side effects seen with less selective agents.
• Oral Therapy Convenience: Once-daily oral dosing supports patient adherence compared with injectable or more complex regimens.
• Alignment with Precision Nephrology Trends: Growing emphasis on biomarker-driven risk stratification and early disease intervention favors atrasentan's positioning.
• Increasing Role of Real-World Evidence (RWE): Post-approval RWE will be important for payer confidence, long-term safety validation, and expansion of treatment guidelines.

Atrasentan Recent Developments

In April 2025, Novartis announced the US Food and Drug Administration (FDA) granted accelerated approval for VANRAFIA (Atrasentan), a potent and selective endothelin A (ETA) receptor antagonist, for the reduction of proteinuria in adults with primary immunoglobulin A nephropathy (IgAN) at risk of rapid disease progression. This is generally defined as a urine protein-to-creatinine ratio (UPCR) >=1.5 g/g. VANRAFIA is a once-daily, non-steroidal, oral treatment that can be added onto supportive care, including a renin-angiotensin system (RAS) inhibitor with or without a sodium-glucose co-transporter-2 (SGLT2) inhibitor.

"Atrasentan Sales Forecast, and Market Size Analysis - 2034" report provides comprehensive insights of Atrasentan for approved indication like Myasthenia gravis; as well as potential indications like Fetal erythroblastosis; Neonatal alloimmune thrombocytopenia; Sjogren's syndrome; and Systemic lupus erythematosus in the 7MM. A detailed picture of Atrasentan's existing usage in approved and anticipated entry and performance in potential indications in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2020 -2034 is provided in this report along with a detailed description of the Atrasentan for approved and potential indications. The Atrasentan market report provides insights about Atrasentan's sales forecast, mechanism of action (MoA), dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of historical and current Atrasentan performance, future market assessments inclusive of the Atrasentan market forecast analysis for approved and potential indications in the 7MM, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in respective indications. It also provides analysis of Atrasentan sales forecasts, along with factors driving its market.

Atrasentan Drug Summary

Atrasentan (brand name VANRAFIA) is an oral, selective endothelin A receptor (ETAR or ETA) antagonist developed by Novartis for treating immunoglobulin A nephropathy (IgAN), a progressive kidney disease characterized by proteinuria. With high selectivity (Ki = 0.034 nM for ETA versus 63.3 nM for ETB), it blocks endothelin-1 binding to ETA receptors on renal cells, reducing glomerular hypertension, efferent arteriolar vasoconstriction, inflammation, fibrosis, and proteinuria while preserving renal function. FDA-approved in 2025 for adults with IgAN at risk of rapid progression, it is dosed once daily (0.75 mg) alongside standard supportive care like renin-angiotensin system blockade, showing clinically meaningful proteinuria reductions in Phase III trials. The report provides Atrasentan's sales, growth barriers and drivers, post usage and approvals in multiple indications.

Atrasentan is in the Phase II stage of clinical development for the treatment of patients with IgA Nephropathy (NCT04573920).

Scope of the Atrasentan Market Report

The report provides insights into:

• A comprehensive product overview including the Atrasentan MoA, description, dosage and administration, research and development activities in approved indications like Myasthenia gravis; as well as potential indications like Fetal erythroblastosis; Neonatal alloimmune thrombocytopenia; Sjogren's syndrome; and Systemic lupus erythematosus.
• Elaborated details on Atrasentan regulatory milestones and other development activities have been provided in Atrasentan market report.
• The report also highlights Atrasentan's cost estimates and regional variations, reported and estimated sales performance, research and development activities in approved and potential indications across the United States, Europe, and Japan.
• The Atrasentan market report also covers the patents information, generic entry and impact on cost cut.
• The Atrasentan market report contains current and forecasted Atrasentan sales for approved and potential indications till 2034.
• Comprehensive coverage of the late-stage emerging therapies for respective indications.
• The Atrasentan market report also features the SWOT analysis with analyst views for Atrasentan in approved and potential indications.

Methodology:

The Atrasentan market report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

Atrasentan Analytical Perspective by DelveInsight

• In-depth Atrasentan Market Assessment

This Atrasentan sales market forecast report provides a detailed market assessment of Atrasentan for approved indication like Myasthenia gravis; as well as potential indications like Fetal erythroblastosis; Neonatal alloimmune thrombocytopenia; Sjogren's syndrome; and Systemic lupus erythematosus in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides current and forecasted Atrasentan sales data uptil 2034.

• Atrasentan Clinical Assessment

The Atrasentan market report provides the clinical trials information of Atrasentan for approved and potential indications covering trial interventions, trial conditions, trial status, start and completion dates.

Atrasentan Competitive Landscape

The report provides Insights on competitors and marketed products within the domain, along with a summary of emerging products and their respective launch dates, posing significant competition in the market.

Atrasentan Market Potential & Revenue Forecast

• Projected market size for the Atrasentan and its key indications
• Estimated Atrasentan sales potential (Atrasentan peak sales forecasts)
• Atrasentan Pricing strategies and reimbursement landscape

Atrasentan Competitive Intelligence

• Number of competing drugs in development (pipeline analysis)
• Atrasentan Market positioning compared to existing treatments
• Atrasentan Strengths & weaknesses relative to competitors

Atrasentan Regulatory & Commercial Milestones

• Atrasentan Key regulatory approvals & expected launch timelines
• Commercial partnerships, licensing deals, and M&A activity

Atrasentan Clinical Differentiation

• Atrasentan Efficacy & safety advantages over existing drugs
• Atrasentan Unique selling points

Atrasentan Market Report Highlights

• In the coming years, the Atrasentan market scenario is set to change due to strong adoption, increased prescriptions and broader uptake in multiple immunological indications; which would expand the size of the market.
• The Atrasentan companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence Atrasentan's dominance.
• Other emerging products for Myasthenia gravis; as well as potential indications like Fetal erythroblastosis; Neonatal alloimmune thrombocytopenia; Sjogren's syndrome; and Systemic lupus erythematosus are expected to give tough market competition to Atrasentan and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of Atrasentan in approved and potential indications.
• Analyse Atrasentan cost, pricing trends and market positioning to support strategic decision-making in the immunology landscape.
• Our in-depth analysis of the forecasted Atrasentan sales data uptil 2034 will support the clients in decision-making process regarding their therapeutic portfolio by identifying the overall scenario of Atrasentan in approved and potential indications.

Key Questions:

• What is the class of therapy, route of administration and mechanism of action of Atrasentan? How strong is Atrasentan's clinical and commercial performance?
• What is Atrasentan's clinical trial status in each individual indications such as Myasthenia gravis; as well as potential indications like Fetal erythroblastosis; Neonatal alloimmune thrombocytopenia; Sjogren's syndrome; and Systemic lupus erythematosus and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the Atrasentan Manufacturers?
• What are the key designations that have been granted to Atrasentan for approved and potential indications? How are they going to impact Atrasentan's penetration in various geographies?
• What is the current and forecasted Atrasentan market scenario for approved and potential indications? What are the key assumptions behind the forecast?
• What are the current and forecasted sales of Atrasentan in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain) and the United Kingdom, and Japan?
• What are the other emerging products available and how are these giving competition to Atrasentan for approved and potential indications?
• Which are the late-stage emerging therapies under development for the treatment of approved and potential indications?
• How cost-effective is Atrasentan? What is the duration of therapy and what are the geographical variations in cost per patient?

Table of Contents

1. Report Introduction

2. Atrasentan Overview in approved indications like Myasthenia gravis; as well as potential indications like Fetal erythroblastosis; Neonatal alloimmune thrombocytopenia; Sjogren's syndrome; and Systemic lupus erythematosus

• 2.1. Product Detail
• 2.2. Atrasentan Clinical Development
  • 2.2.1. Atrasentan Clinical studies
  • 2.2.2. Atrasentan Clinical trials information
  • 2.2.3. Safety and efficacy
• 2.3. Other Developmental Activities
• 2.4. Product Profile

3. Atrasentan Competitive Landscape (Marketed Therapies)

4. Competitive Landscape (Late-stage Emerging Atrasentan Therapies)

5. Atrasentan Market Assessment

• 5.1. Atrasentan Market Outlook in approved and potential indications
• 5.2. 7MM Analysis
  • 5.2.1. Atrasentan Market Size in the 7MM for approved and potential indications
• 5.3. Country-wise Market Analysis
  • 5.3.1. Atrasentan Market Size in the United States for approved and potential indications
  • 5.3.2. Atrasentan Market Size in Germany for approved and potential indications
  • 5.3.3. Atrasentan Market Size in France for approved and potential indications
  • 5.3.4. Atrasentan Market Size in Italy for approved and potential indications
  • 5.3.5. Atrasentan Market Size in Spain for approved and potential indications
  • 5.3.6. Atrasentan Market Size in the United Kingdom for approved and potential indications
  • 5.3.7. Atrasentan Market Size in Japan for approved and potential indications

6. Atrasentan SWOT Analysis

7. Analysts' Views

8. Appendix

• 8.1. Bibliography
• 8.2. Report Methodology

9. DelveInsight Capabilities

10. Disclaimer

11. About DelveInsight

12. Report Purchase Options

List of Tables

• Table 1: Atrasentan, Clinical Trial Description, 2023
• Table 2: Atrasentan, General Description
• Table 3: Competitive Landscape (Marketed Therapies)
• Table 4: Competitive Landscape (Emerging Therapies)
• Table 5: Atrasentan's pricing and cost Assumptions
• Table 6: Atrasentan's Sales Analysis in the 7MM, in USD million (2020-2034)
• Table 7: Atrasentan Market Size in the US, in USD million (2020-2034)
• Table 8: Atrasentan Market Size in Germany, in USD million (2020-2034)
• Table 9: Atrasentan Market Size in France, in USD million (2020-2034)
• Table 10: Atrasentan Market Size in Italy, in USD million (2020-2034)
• Table 11: Atrasentan Market Size in Spain, in USD million (2020-2034)
• Table 12: Atrasentan Market Size in the UK, in USD million (2020-2034)
• Table 13: Atrasentan Market Size in Japan, in USD million (2020-2034)

List of Figures

• Figure 1: Atrasentan's Sales Analysis in the 7MM, USD million (2020-2034)
• Figure 2: Atrasentan Market Size in the United States, USD million (2020-2034)
• Figure 3: Atrasentan Market Size in Germany, USD million (2020-2034)
• Figure 4: Atrasentan Market Size in France, USD million (2020-2034)
• Figure 5: Atrasentan Market Size in Italy, USD million (2020-2034)
• Figure 6: Atrasentan Market Size in Spain, USD million (2020-2034)
• Figure 7: Atrasentan Market Size in the United Kingdom, USD million (2020-2034)
• Figure 8: Atrasentan Market Size in Japan, USD million (2020-2034)